tirzepatide cvot trial Demonstrates Cardioprotective Effects in SURPASS-CVOT A comparison of the effects

The 7.2 mg dosage, called Wegovy HD, is intended forweight lossand long-term weight loss maintenance for adult patients.

In participants with obesity or overweight, withdrawing tirzepatide led to substantial regain of lost weight, whereas continued treatment maintained and augmented initial weight reduction

Lost the weight but still look pregnant

Lose up to 20% of your body weight a year in a healthy and maintainable way with prescription medication.

The antibody co-localization capability of this technology is particularly useful when using inherently cross-reactive reagents such as polyclonal antibodies, although monoclonal antibody cross-reactivity can also be reduced